Extravascular transport of drugs in tumor tissue: Effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures

Journal of Medicinal Chemistry

Volumn 48, Issue 4, 2005, Pages 1079-1087

  Pruijn, Frederik B ^a   Sturman, Joanna R ^a   Liyanage, H D Sarath ^a   Hicks, Kevin O ^a   Hay, Michael P ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

N [3 (2 METHOXYETHYL)PHENYL] 1,2,4 BENZOTRIAZIN 3 AMINE 1,4 DIOXIDE; N PHENYL 1,2,4 BENZOTRIAZIN 3 AMINE 1,4 DIOXIDE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG DIFFUSION; DRUG MECHANISM; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; PARTITION COEFFICIENT; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; TRANSPORT KINETICS;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; DIFFUSION; HT29 CELLS; HUMANS; MODELS, BIOLOGICAL; SOLUBILITY; TRIAZINES;

EID: 13944258034     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049549p     Document Type: Article

References (52)

1. 2, and Fab in tumors. Cancer Res. 1989, 49, 5656-5663.
2. van Osdol, W.; Fujimori, K.; Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier". Cancer Res. 1991, 51, 4776-4784.
3. Rowe-Jones, D. C. The penetration of cytotoxins into malignant tumours. Br. J. Cancer 1968, 22, 155-162.
4. Jain, R. K.; Weissbrod, J. M.; Wei, J. Mass transport in tumors: characterization and applications to chemotherapy. Adv. Cancer Res. 1980, 33, 251-310.
5. 14C]-misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors. Cancer Res. 1985, 45, 1692-1701.
6. Kerr, D. J.; Kaye, S. B. Aspects of cytotoxic drug penetration with particular reference to anthracyclines. Cancer Chemother. Pharmacol. 1987, 19, 1-5.
7. Simpson-Herren, L.; Noker, P. E. Diversity of penetration of anticancer agents into solid tumours. Cell Proliferation 1991, 24, 355-365.
8. Jain, R. K. The next frontier of molecular medicine: delivery of therapeutics. Nat. Med. 1998, 4, 655-657.
9. Tannock, I. F. Conventional cancer therapy: promise broken or promise delayed? Lancet 1998, 351 (Suppl. 2), 9-16.
10. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 1993, 67, 1163-1170.
11. Denny, W. A.; Wilson, W. R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Invest. Drugs 2000, 9, 2889-2901.
12. Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res. 1988, 48, 5947-5952.
13. Siim, B. G.; van Zijl, P. L.; Brown, J. M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer 1996, 73, 952-960.
14. Durand, R. E.; Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol., Biol., Phys. 1992, 22, 689-692.
15. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 641-649.
16. Kyle, A. H.; Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213-220.
17. Baguley, B. C.; Hicks, K. O.; Wilson, W. R. Tumour cell cultures in drug development. In Anticancer Drug Development; Baguley, B. C., Kerr, D. J., Eds.; Academic Press: San Diego, CA, 2002; pp 269-284.
18. Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res. 2003, 63, 5970-5977.
19. Kubinyi, H. Lipophilicity and biological activity. Arzneim.-Forsch. 1979, 29, 1067-1080.
20. Lieb, W. R.; Stein, W. D. Simple diffusion across the membrane bilayer. In Transport and Diffusion across Cell Membranes; Stein, W. D., Ed.; Academic Press: Orlando, FL, 1986; pp 69-112.
21. Cowan, D. S.; Hicks, K. O.; Wilson, W. R. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer, Suppl. 1998, 27, S28-S31.
22. Minchinton, A. I.; Wendt, K. R.; Clow, K. A.; Fryer, K. H. Multilayers of cells growing on a permeable support. An in vitro tumour model. Acta Oncol. 1997, 36, 13-16.
23. Hicks, K. O.; Pruijn, F. B.; Baguley, B. C.; Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino) ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther. 2001, 297, 1088-1098.
24. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Pruijn, F. B.; Anderson, R. F.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 2003, 46, 169-182.
25. Robbins, R. F.; Schofield, K. Polyazabicyclic compounds. Part II. Further derivatives of benzo-1,2,4-triazine. J. Chem. Soc. 1957, 3186-3194.
26. Pazdera, P.; Potacek, M. N-Ethyl substituted 2-nitrophenylguanidines. II Cyclization. Chem. Pap. 1989, 43, 107-112.
27. Norman, R. O. C.; Radda, G. K. The ortho:para ratio in aromatic substitution. Part 1. The nitration of methyl phenethyl ether. J. Chem. Soc. 1961, 3030-3037.
28. Sum, B. G.; Hicks, K. O.; Pullen, S. M.; van Zyl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs. Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
29. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Hobbs, S. M.; Pruijn, F. B.; Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Reviews; Springer, C. J., Ed.; Humana Press: Totowa, NJ, 2003; pp 403-432.
30. Cussler, E. L. Values of diffusion coefficients. In Diffusion, Mass Transfer in Fluid Systems, 2nd ed.; Cussler, E. L., Ed.; Cambridge University Press: Cambridge and New York, 1997; pp 101-141.
31. Cummings, J.; Boyd, G.; Macpherson, J. S.; Wolf, H.; Smith, G.; Smyth, J. F.; Jodrell, D. I. Factors influencing the cellular accumulation of SN-38 and camptothecin. Cancer Chemother. Pharmacol. 2002, 49, 194-200.
32. Schmittmann, G.; Rohr, U. D. Comparison of the permeability surface product (PS) of the blood capillary wall in skeletal muscle tissue of various species and in vitro porous membranes using hydrophilic drugs. J. Pharm. Sci. 2000, 89, 115-127.
33. Artursson, P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 1990, 79, 476-482.
34. Adson, A.; Burton, P. S.; Raub, T. J.; Barsuhn, C. L.; Audus, K. L.; Ho, N. F. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J. Pharm. Sci. 1995, 84, 1197-1204.
35. Dearden, J. C. Molecular structure and drug transport. In Comprehensive Medicinal Chemistry: The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, 1st ed.; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford and New York, 1990; pp 375-411.
36. Mastro, A. M.; Babich, M. A.; Taylor, W. D.; Keith, A. D. Diffusion of a small molecule in the cytoplasm of mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3414-3418.
37. Hicks, K. O.; Siim, B. G.; Pruijn, F. B.; Wilson, W. R. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors. Radiat. Res. 2004, 161, 656-666.
38. Zeman, E. M.; Baker, M. A.; Lemmon, M. J.; Pearson, C. I.; Adams, J. A.; Brown, J. M.; Lee, W. W.; Tracy, M. Structure-activity relationships for benzotriazine di-N-oxides. Int. J. Radiat. Oncol., Biol., Phys. 1989, 16, 977-981.
39. Kelson, A. B.; McNamara, J. P.; Pandey, A.; Ryan, K. J.; Dorie, M. J.; McAfee, P. A.; Menke, D. R.; Brown, J. M.; Tracy, M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des. 1998, 13, 575-592.
40. Goodwin, J. T.; Conradi, R. A.; Ho, N. F.; Burton, P. S. Physicochemical determinants of passive membrane permeability: role of solute hydrogen-bonding potential and volume. J. Med. Chem. 2001, 44, 3721-3729.
41. Stenberg, P.; Luthman, K.; Artursson, P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharm. Res. 1999, 16, 205-212.
42. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
43. Lankelma, J. Tissue transport of anti-cancer drugs. Curr. Pharm. Des. 2002, 8, 1987-1993.
44. Tannock, I. F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001, 20, 123-132.
45. Grote, J.; Süsskind, R.; Vaupel, P. Oxygen diffusivity in tumor tissue (DS-carcinosarcoma) under temperature conditions within the range of 20-40 °C. Pfluegers Arch. 1977, 372, 37-42.
46. Dewhirst, M. W.; Secomb, T. W.; Ong, E. T.; Hsu, R.; Gross, J. F. Determination of local oxygen consumption rates in tumors. Cancer Res. 1994, 54, 3333-3336.
47. Dewhirst, M. W.; Ong, E. T.; Klitzman, B.; Secomb, T. W.; Vinuya, R. Z.; Dodge, R.; Brizel, D.; Gross, J. F. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat. Res. 1992, 130, 171-182.
48. Hoff, P. M.; Saad, E. D.; Ravandi-Kashani, F.; Czerny, E.; Pazdur, R. Phase I trial of i.v. administered tirapazamine plus cyclophosphamide. Anti-Cancer Drugs 2001, 12, 499-503.
49. von Pawel, J.; von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L. O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T. W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J. Clin. Oncol. 2000, 18, 1351-1359.
50. Bedikian, A. Y.; Legha, S. S.; Eton, O.; Buzaid, A. C.; Papadopoulos, N.; Plager, C.; McIntyre, S.; Viallet, J. Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anti-Cancer Drugs 1999, 10, 735-739.
51. Graham, M. A.; Senan, S.; Robin, H., Jr.; Eckhardt, N.; Lendrem, D.; Hincks, J.; Greenslade, D.; Rampling, R.; Kaye, S. B.; von Roemeling, R.; Workman, P. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother. Pharmacol. 1997, 40, 1-10.
52. Johnson, C. A.; Kilpatrick, D.; von Roemeling, R.; Langer, C.; Graham, M. A.; Greenslade, D.; Kennedy, G.; Keenan, E.; O'Dwyer, P. J. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol. 1997, 15, 773-780.